Houdini Bio launches with approximately £1.5 million in combined backing
SCVC led an oversubscribed pre-seed round alongside grant support for the company’s therapeutic DNA platform.
Houdini Bio announced its launch on June 19, 2026, after securing approximately £1.5 million in combined grant and pre-seed funding. The amount attributable to the equity round was not disclosed.
SCVC led the pre-seed, with Deep Science Ventures and Cambridge Enterprise Ventures participating. The backing supported validation of the company’s machine-learning platform for designing therapeutic DNA that resists cellular silencing.
Houdini plans to expand its team and develop partnerships with pharmaceutical and biotechnology companies applying the technology to genetic medicines.
Use of funds
Validate DNA sequence design platform
Expand team
Scale co-development partnerships